Oncolytics Biotech Inc.
ONCY•NASDAQ•Healthcare•Biotechnology

About Oncolytics Biotech

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOJared Kelly
Founded1998
IPO DateNovember 8, 1999
Employees28
CountryCanada
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyCAD - CAD
TypeStock

Contact Information

Websiteoncolyticsbiotech.com
Phone403 670 7377
Address
322 11th Avenue SW, Suite 804 Calgary, AB T2R 0C5 Canada

Corporate Identifiers

CIK0001129928
CUSIP682310875
ISINCA6823108759
SIC2834

Leadership Team & Key Executives

Jared Kelly J.D., L.L.M.
Chief Executive Officer and Director
Kirk J. Look C.A., CPA
Chief Financial Officer
Dr. Thomas C. Heineman M.D., Ph.D.
Chief Medical Officer
Allison Hagerman P.Eng., P.M.P.
Vice President of Product Development
Amy Goodowitz Levin B.S.N., R.N.
Vice President of Clinical Operations
Jon Patton
Director of Investor Relations and Communication
Andrew P. Aromando
Chief Business Officer
John Mark Lievonen B.B.A., CM, F.C.A., FCPA, LLD, M.B.A.
Consultant